探讨放射性碘125(¹²⁵I)粒子植入治疗局部非小细胞肺癌(NSCLC)的近远期疗效。

选择2015年1月到2018年1月无锡市第五人民医院收治的67例局部NSCLC患者作为研究对象，按照随机数字表法将其随机分为研究组32例和对照组35例，对照组采取紫杉醇联合顺铂静脉滴注方案进行化疗，研究组在对照组基础上采取放射性¹²⁵I粒子植入术治疗，比较两组临床疗效，比较两组治疗前后癌胚抗原(CEA)、细胞角质素片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)水平及癌症患者生活质量核心量表(EORTC QLQ-C30)评分，比较两组治疗期间不良反应发生情况及近远期随访生存情况。

研究组治疗后ORR为81.25%显著高于对照组57.14%，差异有统计学意义(P<0.05)。研究组治疗后CYFRA21-1、CA125显著低于治疗前及对照组治疗后(P<0.05)；两组治疗后CEA组内比较显著低于治疗前(P<0.05)。研究组治疗后躯体症状评分显著低于治疗前及对照组治疗后(P<0.05)；两组治疗后总体功能、总体健康评分显著高于治疗前(P<0.05)。研究组不良反应总发生率为53.13%，与对照组37.14%比较，差异无统计学意义(P>0.05)。研究组半年、1年、2年存活率分别为96.88%、87.50%、75.00%，显著高于对照组半年、1年、2年存活率82.86%、65.71%、48.57%，差异有统计学意义(Log-Rank＝5.124，P＝0.024)。

放射性¹²⁵I粒子植入治疗可显著提高局部NSCLC患者近远期生存率，改善患者体内血清肿瘤标志物水平，且安全性良好，临床价值较高。

To study the short-term and long-term efficacy of radioactive iodine 125 (¹²⁵I) seeds implantation in the treatment of local non-small cell lung cancer (NSCLC).

All 67 patients with local NSCLC admitted to the Fifth People′s Hospital of Wuxi City from January 2015 to January 2018 were selected as the research objects and randomly divided into study group 32 cases and control group 35 cases according to random number table method; The control group was treated with paclitaxel combined with cisplatin for chemotherapy, while the observation group was treated with radioactive ¹²⁵I seed implantation on the basis of the control group, The clinical efficacy, CEA, CYFRA21-1, CA125 and EORTC QLQ-C30 scores were compared between the two groups before and after treatment, and the adverse reactions and The incidence of adverse reactions and short-term and long-term follow-up survival of the two groups were compared.

The ORR of the study group was 81.25%, which was significantly higher than that of the control group (57.14%) (P<0.05). After treatment, CYFRA21-1 and CA125 in the study group were significantly lower than those before treatment and after treatment in the control group (P<0.05); the CEA levels in the two groups after treatment were significantly lower than those before treatment (P<0.05). The body symptom score of the study group after treatment was significantly lower than that before treatment and after treatment in the control group (P<0.05); the overall function and overall health score of the two groups after treatment were significantly higher than those before treatment (P<0.05). The total incidence of adverse reactions in the study group was 53.13%, compared with 37.14% in the control group, the difference was not statistically significant (P>0.05). The half year, one-year and two-year survival rates of the study group were 96.88%, 87.50% and 75.00%, which were significantly higher than those of the control group (82.86%, 65.71% and 48.57%) respectively, and the difference was statistically significant (Log-Rank=5.124, P=0.024).

Radioactive ¹²⁵I seed implantation therapy can significantly improve the short-term and long-term survival rate of patients with local NSCLC, improve the serum tumor markers level of patients, and has good safety and high clinical value.